Detail akcie Biosynex online

Business Summary: Biosynex SA is a France-based company that specializes in the research, development and manufacture of in-vitro diagnostic kits aimed at health professionals. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). It operates through Fumouze Diagnostics and SR2B.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Biosynex SA revenues decreased 6% to EUR50.5M. Net loss applicable to common stockholders increased from EUR20.9M to EUR48.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Equity Earnings - Net of Tax increase of 15% to EUR115K (losses), Taxes & Duties increase of 3% to EUR514K (expense).